Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 30Recruiting 21Terminated 17Unknown 12Active not recruiting 9Not yet recruiting 8Withdrawn 4Suspended 1Enrolling by invitation 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 14Hematologic Neoplasms 13Precursor Cell Lymphoblastic Leukemia-Lymphoma 11Leukemia, Lymphocytic, Chronic, B-Cell 6Myelodysplastic Syndromes 5Lymphoma, Non-Hodgkin 4Lymphoma 4Leukemia 4Neoplasms 3Multiple Myeloma 3Melanoma 3Lymphoma, B-Cell 3Thrombocytopenia 2Prostatic Neoplasms 2Pain 2Lymphoma, Mantle-Cell 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Follicular 2Lymphoma, B-Cell, Marginal Zone 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Leukemia, B-Cell 2Hematologic Diseases 2Acute Pain 2Wounds and Injuries 1Waldenstrom Macroglobulinemia 1Urogenital Diseases 1Recurrence 1Prostatic Neoplasms, Castration-Resistant 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1

Interventions

Cytarabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Enrolling by invitation × Neoplasm, Residual × Other hematologic neoplasm × Clear all
NCT07537257 2026-04-17

VEN+IDAC vs IDAC in AML

Guangdong Second Provincial General Hospital

Phase 2/3 Enrolling by invitation
232 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡